★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
AbbVie Inc.
ABBV · New York Stock Exchange
Partial score covering 85% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
AbbVie is a U.S. biopharmaceutical company concentrated in Immunology and diversified across Neuroscience, Oncology, Aesthetics, Eye Care and other specialty products. Its clearest moat is asset-specific patents and regulatory exclusivity: Rinvoq settlement licenses delay expected U.S. generic entry to April 2037 if pediatric exclusivity applies, while Skyrizi and Rinvoq generated $6.602B of Q1 2026 revenue. The FDA expanded Skyrizi to pediatric psoriatic disease on June 26, 2026. Botox has meaningful prescriber familiarity and a stronger consumer brand in aesthetics, but those scores are below maximum because providers and patients can switch. Generic regulatory requirements shared by all credible drugmakers are not treated as standalone moats, leaving mature Eye Care and Other products without a separately evidenced advantage.
Primary segment
Immunology
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
6 segments · 10 tags
Updated 2026-07-12
Segments
Immunology
Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)
Revenue
48.9%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Oncology
Oncology therapeutics (hematologic malignancies and solid tumors; targeted therapies, combinations, and ADCs)
Revenue
10.9%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Neuroscience
Neuroscience therapies (migraine, psychiatry, movement disorders; includes therapeutic neurotoxin)
Revenue
17.5%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Aesthetics
Medical aesthetics (aesthetic neurotoxins, dermal fillers, and related clinic-sold products)
Revenue
7.9%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Eye Care
Ophthalmology pharmaceuticals (glaucoma, retina/implant therapies, dry eye and other eye care)
Revenue
3.4%
Structure
Competitive
Pricing
weak
Share
—
Peers
Other Key Products
Other specialty/legacy pharmaceuticals (e.g., HCV antivirals, gastrointestinal, metabolic and other categories)
Revenue
11.4%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Immunology
Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)
Revenue_share is derived from AbbVie FY2025 worldwide net revenues by product table: Immunology products (Skyrizi, Rinvoq, and Humira) generated $29.894B of $61.160B total net revenues for the year ended 2025-12-31 (Form 10-K filed 2026-02-20).
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Core cash flows are protected by patents/regulatory exclusivity. AbbVie disclosed settlement/license agreements that (assuming pediatric exclusivity) delay U.S. generic entry for Rinvoq until April 2037; Skyrizi/Rinvoq are identified as significant IP in the FY2025 10-K.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity and biosimilar/generic entry (rapid net price and volume erosion)
- Patent challenges, adverse litigation outcomes, or settlements on less favorable terms
- Payer/formulary pressure and step-edits reducing realized net pricing
Leading indicators
- Skyrizi and Rinvoq net revenue growth vs prior year
- Share trends in psoriasis/IBD/RA and other labeled indications
- Formulary positioning and rebate pressure in U.S. channels
Counterarguments
- Therapeutic areas are crowded; clinical differentiation can narrow as competitors launch new agents
- Large payers can force switches or limit access, blunting pricing leverage despite IP
Oncology
Oncology therapeutics (hematologic malignancies and solid tumors; targeted therapies, combinations, and ADCs)
Revenue_share is derived from AbbVie FY2025 worldwide net revenues by product table: Oncology products (Imbruvica, Venclexta, Elahere, Epkinly, and Other Oncology) generated $6.655B of $61.160B total net revenues for the year ended 2025-12-31 (Form 10-K filed 2026-02-20).
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivity protect branded oncology products, but durability varies by asset and can be eroded by competition, lifecycle maturity, and policy-driven price compression.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Medicare price negotiation and broader reimbursement pressure
- Generic/biosimilar entry post-exclusivity
- Share loss from superior regimens and new modalities
Leading indicators
- Net revenue trend for major oncology brands
- Clinical readouts for follow-on/lifecycle indications
- Policy milestones in Medicare negotiation cycles
Counterarguments
- Patent protection may be less valuable late in lifecycle if clinical positioning weakens
- Competitors can bundle and combine therapies, shifting demand away from single assets
Neuroscience
Neuroscience therapies (migraine, psychiatry, movement disorders; includes therapeutic neurotoxin)
Revenue_share is derived from AbbVie FY2025 worldwide net revenues by product table: Neuroscience products (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev, Duodopa, and Other Neuroscience) generated $10.699B of $61.160B total net revenues for the year ended 2025-12-31 (Form 10-K filed 2026-02-20).
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Therapeutic Botox is a long-established neurotoxin with broad clinical use across approved indications, supporting prescriber familiarity and patient willingness to continue therapy.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Competing neurotoxins or novel therapeutics reducing demand
- Safety issues, label changes, or reimbursement tightening
- Greater payer restrictions on specialty therapies
Leading indicators
- Botox Therapeutic net revenue growth and utilization trends
- Competitive launches and comparative clinical data
- Reimbursement and coverage policy changes
Counterarguments
- Clinical preference can shift if competitors offer better efficacy, safety, or convenience
- Brand trust may not prevent payer-driven switches
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents/exclusivity protect major neuroscience brands, but policy can compress economics. Medicare price negotiation selection indicates potential future net price pressure for certain molecules (e.g., Vraylar).
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Medicare negotiation and broader drug pricing reforms
- Generic entry post-exclusivity
- Share loss to superior or lower-cost competitors
Leading indicators
- Policy milestones for negotiated price publication and implementation
- Net revenue and TRx share trends for key brands
- Patent litigation milestones and exclusivity timelines
Counterarguments
- IP does not guarantee durable economics if payers and policy compress net pricing
- Neuroscience markets often support multiple differentiated therapies with rapid switching
Aesthetics
Medical aesthetics (aesthetic neurotoxins, dermal fillers, and related clinic-sold products)
Revenue_share is derived from AbbVie FY2025 worldwide net revenues by product table: Aesthetics products (Botox Cosmetic, Juvederm Collection, and Other Aesthetics) generated $4.860B of $61.160B total net revenues for the year ended 2025-12-31 (Form 10-K filed 2026-02-20).
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Botox Cosmetic and Juvederm are long-standing brands with broad provider adoption and consumer awareness; AbbVie positions the portfolio as holding leading market positions across major aesthetics markets.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Consumer demand declines in recessions / discretionary spending weakness
- Competition from alternative toxins/fillers and aggressive provider discounting
- Reputational damage from safety issues or social/media backlash
Leading indicators
- Botox Cosmetic and Juvederm revenue trends and pricing/mix commentary
- Provider inventory levels and destocking/restocking cycles
- Competitive launch cadence and pricing/promotional intensity
Counterarguments
- Aesthetics switching costs can be low for price-sensitive consumers and providers
- New entrants can gain share via discounting, influencer marketing, or comparable outcomes
Eye Care
Ophthalmology pharmaceuticals (glaucoma, retina/implant therapies, dry eye and other eye care)
Revenue_share is derived from AbbVie FY2025 worldwide net revenues by product table: Eye Care products (Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, and Other Eye Care) generated $2.109B of $61.160B total net revenues for the year ended 2025-12-31 (Form 10-K filed 2026-02-20).
Insufficient segment-specific evidence to assign a moat claim.
Other Key Products
Other specialty/legacy pharmaceuticals (e.g., HCV antivirals, gastrointestinal, metabolic and other categories)
Revenue_share is derived from AbbVie FY2025 worldwide net revenues by product table: Other Key Products and residual other products generated $6.943B of $61.160B total net revenues for the year ended 2025-12-31 (Form 10-K filed 2026-02-20).
Insufficient segment-specific evidence to assign a moat claim.
Evidence
no generic entry for any upadacitinib tablets is expected prior to April 2037 in the United States.
Direct company disclosure extending expected U.S. generic entry timing for Rinvoq (conditional on pediatric exclusivity).
composition of matter patents ... expected to expire in 2033.
The 10-K highlights Skyrizi and Rinvoq composition-of-matter patents as significant and expected to expire in 2033 (baseline before later settlement updates).
Explains AbbVie's reliance on patents and regulatory exclusivity to protect products and delay generic/biosimilar entry.
Lists Imbruvica among the Part D drugs selected for negotiation for initial price applicability year 2026, signaling pricing pressure risk for the franchise.
The filing describes Botox Therapeutic as approved in major markets for multiple indications, consistent with a durable prescriber/patient franchise.
Showing 5 of 7 sources.
Risks & Indicators
Erosion risks
- Loss of exclusivity and biosimilar/generic entry (rapid net price and volume erosion)
- Patent challenges, adverse litigation outcomes, or settlements on less favorable terms
- Payer/formulary pressure and step-edits reducing realized net pricing
- U.S. drug pricing policy changes (rebates, negotiation frameworks, reimbursement changes)
- Competing mechanisms (new biologics, oral therapies, or novel modalities) shifting standards of care
- Medicare price negotiation and broader reimbursement pressure
Leading indicators
- Skyrizi and Rinvoq net revenue growth vs prior year
- Share trends in psoriasis/IBD/RA and other labeled indications
- Formulary positioning and rebate pressure in U.S. channels
- Patent litigation docket / settlement announcements for key assets
- Pipeline readouts and additional indication approvals
- Net revenue trend for major oncology brands
Research ABBV elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.